Salicylate treatment in Kawasaki disease

high dose or low dose?

Teiji Akagi, H. Kato, O. Inoue, N. Sato

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Salicylate is the basic therapy for Kawasaki disease, however its optimal dose is controversial. We investigated the therapeutic efficacy of high dose (100 mg/kg per day, n=30) versus low dose (30 mg/kg per day, n=30) salicylate. Duration of fever, SGPT, serum salicylate, plasma thromboxane B2 (TxB2) and 6-ketoprostaglandin F1α (PGF1α) levels were compared before enrollment and on days 4,7 and 14 of treatment. In the high dose group, duration of fever was significantly shorter than that of the low dose group (3.2±0.3 versus 5.4±0.8 days, P2 production was completely blocked in both groups, and plasma 6-keto-PGF1α levels in the high dose group on day 14 was lower than that in the low dose group (39±8 versus 159±65 pg/ml, P

Original languageEnglish
Pages (from-to)642-646
Number of pages5
JournalEuropean Journal of Pediatrics
Volume150
Issue number9
DOIs
Publication statusPublished - Jul 1991
Externally publishedYes

Fingerprint

Mucocutaneous Lymph Node Syndrome
Salicylates
Fever
Thromboxane B2
Alanine Transaminase
Therapeutics
Serum
prostaglandin F1

Keywords

  • Kawasaki disease
  • Liver function
  • Prostacyclin
  • Salicylate
  • Thromboxane B

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Salicylate treatment in Kawasaki disease : high dose or low dose? / Akagi, Teiji; Kato, H.; Inoue, O.; Sato, N.

In: European Journal of Pediatrics, Vol. 150, No. 9, 07.1991, p. 642-646.

Research output: Contribution to journalArticle

Akagi, Teiji ; Kato, H. ; Inoue, O. ; Sato, N. / Salicylate treatment in Kawasaki disease : high dose or low dose?. In: European Journal of Pediatrics. 1991 ; Vol. 150, No. 9. pp. 642-646.
@article{ec48800edf3546b0b52bb4ec031f9b56,
title = "Salicylate treatment in Kawasaki disease: high dose or low dose?",
abstract = "Salicylate is the basic therapy for Kawasaki disease, however its optimal dose is controversial. We investigated the therapeutic efficacy of high dose (100 mg/kg per day, n=30) versus low dose (30 mg/kg per day, n=30) salicylate. Duration of fever, SGPT, serum salicylate, plasma thromboxane B2 (TxB2) and 6-ketoprostaglandin F1α (PGF1α) levels were compared before enrollment and on days 4,7 and 14 of treatment. In the high dose group, duration of fever was significantly shorter than that of the low dose group (3.2±0.3 versus 5.4±0.8 days, P2 production was completely blocked in both groups, and plasma 6-keto-PGF1α levels in the high dose group on day 14 was lower than that in the low dose group (39±8 versus 159±65 pg/ml, P",
keywords = "Kawasaki disease, Liver function, Prostacyclin, Salicylate, Thromboxane B",
author = "Teiji Akagi and H. Kato and O. Inoue and N. Sato",
year = "1991",
month = "7",
doi = "10.1007/BF02072625",
language = "English",
volume = "150",
pages = "642--646",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Salicylate treatment in Kawasaki disease

T2 - high dose or low dose?

AU - Akagi, Teiji

AU - Kato, H.

AU - Inoue, O.

AU - Sato, N.

PY - 1991/7

Y1 - 1991/7

N2 - Salicylate is the basic therapy for Kawasaki disease, however its optimal dose is controversial. We investigated the therapeutic efficacy of high dose (100 mg/kg per day, n=30) versus low dose (30 mg/kg per day, n=30) salicylate. Duration of fever, SGPT, serum salicylate, plasma thromboxane B2 (TxB2) and 6-ketoprostaglandin F1α (PGF1α) levels were compared before enrollment and on days 4,7 and 14 of treatment. In the high dose group, duration of fever was significantly shorter than that of the low dose group (3.2±0.3 versus 5.4±0.8 days, P2 production was completely blocked in both groups, and plasma 6-keto-PGF1α levels in the high dose group on day 14 was lower than that in the low dose group (39±8 versus 159±65 pg/ml, P

AB - Salicylate is the basic therapy for Kawasaki disease, however its optimal dose is controversial. We investigated the therapeutic efficacy of high dose (100 mg/kg per day, n=30) versus low dose (30 mg/kg per day, n=30) salicylate. Duration of fever, SGPT, serum salicylate, plasma thromboxane B2 (TxB2) and 6-ketoprostaglandin F1α (PGF1α) levels were compared before enrollment and on days 4,7 and 14 of treatment. In the high dose group, duration of fever was significantly shorter than that of the low dose group (3.2±0.3 versus 5.4±0.8 days, P2 production was completely blocked in both groups, and plasma 6-keto-PGF1α levels in the high dose group on day 14 was lower than that in the low dose group (39±8 versus 159±65 pg/ml, P

KW - Kawasaki disease

KW - Liver function

KW - Prostacyclin

KW - Salicylate

KW - Thromboxane B

UR - http://www.scopus.com/inward/record.url?scp=0025884613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025884613&partnerID=8YFLogxK

U2 - 10.1007/BF02072625

DO - 10.1007/BF02072625

M3 - Article

VL - 150

SP - 642

EP - 646

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 9

ER -